Elbasvir, Grazoprevir
Indications
Elbasvir, Grazoprevir is used for:
ELBASVIR
Elbasvir, when used in combination with grazoprevir as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.
GRAZOPREVIR
Grazoprevir is indicated in combination with elbasvir (as the fixed dose combination product Zepatier) with or without ribavirin for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
Elbasvir, when used in combination with grazoprevir as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.
GRAZOPREVIR
Grazoprevir is indicated in combination with elbasvir (as the fixed dose combination product Zepatier) with or without ribavirin for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Elbasvir, Grazoprevir :
Mechanism of Action
ELBASVIR
Elbasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural protein 5A (NS5A), which is essential for viral RNA replication and virion assembly. By combining two direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles (elbasvir and grazoprevir) into the fixed dose combination product Zapatier, this medication targets HCV at multiple steps in the viral lifecycle with improved resistance rates.
GRAZOPREVIR
Grazaprevir is a second generation NS3/4a protease inhibitor use to inhibit viral HCV replication. NS3/4a protease is an integral part of viral replication as it is responsible for cleaving the long polypeptide produced following translation of the viral genome. By inhibiting protease activity, grazoprevir prevents the formation of structural and nonstructural proteins required for replication and assembly (E1, E2, NS2, NS3, NS4A, NS4B, NS5A and NS5B).
Elbasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural protein 5A (NS5A), which is essential for viral RNA replication and virion assembly. By combining two direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles (elbasvir and grazoprevir) into the fixed dose combination product Zapatier, this medication targets HCV at multiple steps in the viral lifecycle with improved resistance rates.
GRAZOPREVIR
Grazaprevir is a second generation NS3/4a protease inhibitor use to inhibit viral HCV replication. NS3/4a protease is an integral part of viral replication as it is responsible for cleaving the long polypeptide produced following translation of the viral genome. By inhibiting protease activity, grazoprevir prevents the formation of structural and nonstructural proteins required for replication and assembly (E1, E2, NS2, NS3, NS4A, NS4B, NS5A and NS5B).